FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 7, 2006, Pages 770-778

  Duong, Cuong P ^a   Hicks, Rodney J ^a   Weih, Leann ^a   Drummond, Elizabeth ^a   Leong, Trevor ^a   Michael, Michael ^a   Thomas, Robert J S ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Chemoradiotherapy; FDG PET; Impact; Oesophageal cancer; Tumour response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPLETE METABOLIC RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; COMBINED MODALITY THERAPY; DRUG THERAPY; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745540132     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0040-z     Document Type: Article

References (39)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):2-8
2. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990 77(8):845-857
3. Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002;38(2):300-313
4. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10(7):754-761
5. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185(6):538-543
6. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88(3):338-356
7. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Reference Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004;91(2):199-204
8. Jones DR, Detterbeck FC, Egan TM, Parker LA Jr, Bernard SA, Tepper JE. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997;64(1):185-91; discussion 191-192
9. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85(5):1026-1032
10. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66(9):827-831
11. Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999;67(5):1466-1469
12. Zuccaro G Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, et al Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999;94(4):906-912
13. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22(5):900-908
14. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19(12):3058- 3065
15. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, et al Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85(10):1403-1406
16. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233(3):300-309
17. DeYoung CM, Suntharalingam M, Line BR, Doyle LA, Krasna MJ. The ability of whole body FDG18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer. A prospective phase II trial. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S165-S166
18. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21(3):428-432
19. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13(3):361-368
20. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184(3):279-283
21. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101(8):1776-1785
22. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78(4):1152-1160
23. Duong C, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJS, et al Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging. DOI 10.1007/s00259-005-0028-8
24. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21(7):1285-1292
25. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, et al Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60(2):412-418
26. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, et al Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112(4):262-268
27. 18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003;4(1):43-49
28. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42(11):1596-1604
29. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004;27(2):164-171
30. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43(4):492-499
31. Duong CP, Demitriou H, Williams D, Weih L, Thompson A, Phillips WA, et al Clinical impact of FDG-PET on management of esophageal cancer [abstract]. Ann Surg Oncol 2004;11:S53
32. Hutton BF, Braun M, Thurfjell L, Lau DY. Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging 2002;29(4):559-577
33. Shreve PD. Adding structure to function. J Nucl Med 2000;41(8):1380-1382
34. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44(8):1200-1209
35. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44(11):1797-1803
36. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64(3):770-6; discussion 776-777
37. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168(2):417-424
38. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999;72(858):525-529
39. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol 1998;53(9):659-665